Acrivon (ACRV): Insider acquired 225,000 options at $1.81

Mirza Mansoor Raza, the company Chief Medical Officer, reported acquiring 225,000 stock options in Acrivon Therapeutics, Inc. (ACRV) on 10/01/2025.

Rhea-AI Filing Summary

Mirza Mansoor Raza, the company Chief Medical Officer, reported acquiring 225,000 stock options in Acrivon Therapeutics, Inc. (ACRV) on 10/01/2025. The options carry an exercise price of $1.81 and are reported as acquired (Transaction Code A), leaving the reporting person with 225,000 derivative securities beneficially owned following the transaction. The filing states vesting terms: 25% vests on November 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continued service. The Form 4 was signed by an attorney-in-fact on 10/03/2025.

Positive

• 225,000 options acquired at an $1.81 exercise price, increasing the reporting person's direct ownership
• Vesting schedule aligns incentives: 25% vests on Nov 1, 2026, remainder vests over 36 months

Negative

• None.

Insights

Corporate Insider Transactions Analyst

Insider acquired 225,000 options at $1.81 with multi-year vesting.

The filing documents an acquisition of 225,000 stock options by the Chief Medical Officer of Acrivon (ACRV) on 10/01/2025. The options carry an exercise price of $1.81 and are reported as directly owned following the transaction.

The vesting schedule is explicit: 25% vests on November 1, 2026, then the remainder vests in 36 monthly installments thereafter, contingent on continued service. This creates a long-term retention structure rather than immediate share dilution.

Insider Trade Summary

Grant/Award: 225,000 shares

Grant/Award 1 txn

Insider Mirza Mansoor Raza

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	225,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 225,000 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the shares subject to the option vest on November 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

FAQ

What transaction did Mirza Mansoor Raza file for ACRV?

The filing reports acquisition of 225,000 stock options on 10/01/2025 (Transaction Code A).

What is the exercise price of the options reported on the Form 4?

The options have an exercise price of $1.81 per share.

How many shares does the reporting person beneficially own after the transaction?

The report shows the reporting person beneficially owns 225,000 derivative securities following the transaction.

When do the reported options begin to vest?

The filing states 25% vests on November 1, 2026, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to continued service.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by Adam D. Levy, Attorney-in-Fact on 10/03/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mirza Mansoor Raza

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.81	10/01/2025		A		225,000		(1)	09/30/2035	Common Stock	225,000	$0	225,000	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option vest on November 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.